Minoxidil 5 %: Topical application of minoxidil 5%
PRP injection: 3 PRP injections one month apart
Nanofat injection: Single nanofat injection
Study summary
Androgenetic alopecia is a condition that bothers a lot of people. The disadvantage of the FDA approved topical minoxidil is that the patient needs to be compliant every day for extended periods of time. This is the main reason why this study is being conducted, to see if a single nanofat injection is superior to applying either topical Minoxidil or PRP
Eligibility
Sex
ALL
Min age
18 Years
Max age
50 Years
Healthy volunteers
No
Inclusion criteria:
* Adults (ages 18-50).
* A clinical diagnosis of androgenetic alopecia confirmed by dermoscopy of both males and females.
* No previous topical treatment used in the past 3 months.
Exclusion criteria:
* Alopecia totalis and alopecia universalis.
* Cicatricial alopecia.
* Other causes of hair loss such as immunological disease.
* Skin disease in the affected area.
* Hypersensitivity or allergy to any of the treatment products used.
* Patients using treatment (topical or systemic) for androgenetic alopecia in the last 3 months.
* Pregnant and lactating females.
* Patients with a history of hypertrophic scars or keloid formation.
* Patients with active infection at the site of the lesion.
* Skin disease in the affected area.
* Hamilton norwood scale stage 6 and 7
* Ludwig Scale stage 3
Primary outcome measure(s)
Clinical improvement by using trichoscopy and photographs — All patients will be evaluated at Day 1 and at 6, 12 and 16 weeks. Photographs using Hamilton norwood scale for males and Ludwig Scale for females
Trichoscopic improvement — All patients will be evaluated at Day 1 and at 6, 12 and 16 weeks. Including hair diameter diversity
patient satisfaction score — All patients will be evaluated at Day 1 and at 6, 12 and 16 weeks. It will be used for objective evaluation:
* 0 to 25% change = not satisfied,
* 26 to 50% = mildly satisfied,
* 51 to 75% = moderately satisfied,
* 76 to 100% = very satisfied.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.